dual nucleoside reverse transcriptase and polymerase inhibitor (Presidio)
N/A
Report date: 2025/06/11 20:01:15
NME
Base Information
Drug Namedual nucleoside reverse transcriptase and polymerase inhibitor (Presidio)
Drug Alias Name
Classification
Mechanisms of Action
Targets
Therapy Area/Indications
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/Territory
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesMedivir AB
China Registration ClassN/A
Develop Information
Active CompaniesN/A
Inactive CompaniesMedivir ABPresidio Pharmaceuticals Inc
Active IndicationsN/A
Inactive Indications
Other Information
ATC CodeN/A
Related LinksN/A